Immunome announced that Abzena was selected as Immunome’s partner research organization for IMM-BCP-01, an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target multiple SARS-CoV-2 antigens. Abzena will work with Immunome to produce the antibody cocktail for clinical testing. In July 2020, Immunome was awarded a $13.3 million agreement executed by the United States Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support this program.
“Immunome has used an innovative biologics research platform to conduct large-scale B cell interrogation of COVID-19 super-responders to identify suitable antibodies. Sarma and his team at Immunome are visionary scientists and leaders in the field and we are very honored to have been selected as the service provider of choice for clinical good manufacturing practice (GMP) manufacturing of the Immunome antibody cocktail. We strongly believe in the potential clinical benefit of this agent and look forward to helping patients in need,” Jonathan Goldman, MD, CEO of Abzena, said.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“We selected Abzena as our Contract Development and Manufacturing Organization (CDMO) partner due to scientific expertise, flexibility and ability to execute on our timeline, critical in these times when rapid response to the pandemic is required. We are excited that Jonathan and his team share our passion for science and delivering high quality patient outcomes. We hope to positively impact the landscape of the global pandemic through our new antibody-based therapeutic approach,” Purnanand Sarma, PhD, CEO of Immunome, said.